In short: Classic vaccines have picked most of the low-hanging fruit: stable-antigen pathogens tamed by robust neutralizing antibodies, leaving the real fun to TB, HIV and other shape-shifters that demand sophisticated T-cell and broadly protective designs. Complex pathogens now drive work on universal influenza, more durable COVID-19 vaccines and dengue formulations that protect without triggering antibody-dependent enhancement. Platform technologies like mRNA make antigens almost on-demand, but the true rate-limiter is still slow, expensive clinical and regulatory machinery, so timelines are measured in years, not press releases. Data science and AI can optimize targets, epitopes and trial designs, yet remain powerful copilots rather than pilots; empiric clinical evidence still has veto power. In high-income Western settings, COVID-19 policy is drifting toward risk-based, seasonal vaccination while adult and maternal schedules expand, even as hesitancy and service gaps resurrect measles and pertussis. In LMICs, the agenda is dominated by catching up missed children and keeping outbreaks at bay on...
🔒 Premium Content - For Free
Unlock this content by becoming a Global Health Press subscriber. Join for exclusive articles, expert research, and valuable insights!
